Credit: Getty Images. The randomized, double-blind, placebo-controlled, parallel-group PRIME2 study included 160 patients with prurigo nodularis. Positive topline results from a phase 3 trial ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab ...
Prurigo nodularis (PN) is a skin condition marked by extremely itchy bumps that form due to repeated scratching, picking, or rubbing. The itch-scratch cycle — where itching prompts scratching, which ...
Prurigo nodularis is a rare, potentially debilitating, inflammatory skin disease characterized by disfiguring skin nodules often covering extensive areas of the body, and an intense and chronic itch ...
- Response observed as early as week 1 and durable for up to 16 weeks -- Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications -- Phase 2 ...
Please provide your email address to receive an email when new articles are posted on . Dupixent improved itch and skin lesions in patients with uncontrolled prurigo nodularis in a phase 3 clinical ...
The field of prurigo nodularis has seen landmark updates in the past 5 years, with clinicians expecting more potential ...
Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this ...
The U.S. Food and Drug Administration has approved Galderma's Nemluvio (nemolizumab) for adult patients living with prurigo nodularis. Nemluvio, administered as a prefilled pen for subcutaneous ...
The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...
The first and only treatment for the disabling skin condition prurigo nodularis has been approved by the Food and Drug Administration in a development a D.C. dermatologist calls “huge.” Prurigo ...
Nemolizumab (Mitchga) is gearing up to be a potential new treatment for prurigo nodularis, with further phase 3 data supporting its efficacy and safety reported this month at the annual meeting of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results